- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Dec 14, 2021
Product Development
Dec. 13 Quick Takes: Bellus headed for Phase III in chronic cough
Plus: Veru’s Entadfi approved, Brii asset on hold and updates from Arbutus, BrainStorm and Vaccitech
BioCentury | May 10, 2019
Emerging Company Profile
HopeMed: Targeting PRLR for chronic diseases
How HopeMed’s anti-PRLR antibody could treat endometriosis, alopecia with fewer side effects
BioCentury | Oct 14, 2013
Strategy
Reviving Merck
Why it will take years to see Perlmutter's effect on R&D at Merck
Items per page:
1 - 10 of 23